The University of Michigan is getting a $10 million boost to research and expand the use of histotripsy, a medical advance pioneered on the Ann Arbor campus that uses precisely targeted ultrasound waves to destroy cancerous tumors without damaging surrounding tissue.

Already approved by the U.S. Food and Drug Administration to treat liver tumors, U-M leaders say the money will be used to advance the technology and research so histotripsy could become a future treatment option for people with kidney cancer, pancreatic cancer, brain tumors, hemorrhagic stroke, blood clots, epilepsy and more.

“Michigan is at its best when our brightest minds connect to tackle the most consequential challenges of our time,” said U-M President Domenico Grasso during a Sept. 10 news conference, announcing the $10 million donation from multiple sources, including the university’s engineering department, private donors and HistoSonics, the U-M startup that commercialized the technology.